Objective: The aim of this study was to conduct a pilot study for the feasibility of planning a definitive clinical trial comparing traditional acupuncture (TA) with sham acupuncture (SA) and waiting control (WC) on menopauserelated vasomotor symptoms (VMS), quality of life, and the hypothalamic-pituitary-adrenal axis in perimenopausal and postmenopausal women.
V asomotor symptoms (VMS) are experienced by 68% to 82% of women transitioning through menopause and are the primary reason that women use hormone therapy (HT). 1, 2 Although HT is effective for the reduction of VMS, concern regarding the findings of the Women's Health Initiative 3<9 specific to the greater risks compared with health benefits of HT has fueled interest in alternative nonhormonal treatments. Other pharmaceutical agents such as venlafaxine and gabapentin have been used with moderate success but can also produce undesirable adverse effects, 10 and longer term safety is relatively unknown. A nonpharmacological intervention that can be used to reduce VMS with little to no adverse effects is acupuncture. Prior studies of acupuncture on VMS has suggested that acupuncture is no better than placebo; however, these studies have been limited by relatively small sample sizes, relatively short duration, and absence of or inadequate controls. Furthermore, there has been limited investigation of the impact of acupuncture on mechanistic pathways of VMS.
Dysfunction of the central thermoregulatory center associated with declining ovarian function is the leading hypothesized etiology of VMS. 11 An understanding of the hypothalamicpituitary-ovarian axis provides a framework from which to investigate additional/alternative hypothesized mechanistic pathways of VMS. It is known that the hypothalamic-pituitaryadrenal (HPA) axis under stressful conditions can negatively affect the hypothalamic-pituitary-ovarian axis 12, 13 ; however, there is limited knowledge regarding the HPA axis, specifically cortisol (F) production and VMS. Recent data suggest that women with severe VMS have increased urinary F secretion (910 ng/mg creatinine) during the late menopausal transition stage compared with women with less severe VMS, despite the fact that the groups did not differ in age, body mass index, follicle-stimulating hormone or estrone glucuronide levels, health practices, exercise, mood, sleep, cognition, or stress. 14 Prior studies suggest that acupuncture reduces hot flashes better than usual care alone, as well as antidepressant medication, but not significantly better than sham acupuncture (SA), suggestive of a placebo effect. 15<18 Other studies suggest that acupuncture may decrease VMS relatively longer compared with other interventions, 17,19<22 suggesting a mechanistic pathway more complex than a psychological placebo pathway. We conducted a pilot study for feasibility, outcome determination, and sample size estimation purposes to plan a definitive clinical trial comparing traditional acupuncture (TA) with SA and waiting control (WC) on VMS, menopause-related quality of life (QOL), and the potential VMS mechanistic pathway of the HPA axis in perimenopausal and postmenopausal women.
METHODS
The study was approved by the Cedars-Sinai Institutional Review Board.
Study overview
We designed a randomized, single-blind, placebo-controlled trial of equal randomization into TA, SA, or WC. The intervention period was 3 months (12 wk), with the TA and SA participants receiving treatment three times per week for a maximal total of 36 treatments. Data and specimen collections were carried out at weeks 0 (entry), 5 (TA and SA: hot flash diary only), and 12 (exit).
Participants
We recruited 33 women through mailing advertisements to women within a 5-mile radius, as well as advertisements placed on the Cedars-Sinai Medical Center intranet. We recruited women older than 40 years with menopause-related VMS. Eligibility criteria included at least seven hot flashes per day and at least one missed menstrual cycle or spontaneous or medically induced menopause. Exclusion criteria included concomitant illness with reasonable likelihood of limiting survival to less than 1 year; current substance abuse; known, suspected, or planned pregnancy in the next year; other concomitant menopause treatment; participating in acu-puncture treatment or formal psychological stress management program within the last year; participating in another treatment of VMS, unless willing to stop it 4 weeks in advance of participation; HIV infection; chronic or active hepatitis; or other blood-borne illness.
Randomization
To eliminate bias in treatment assignment, the participants were allocated to one of three study arms with equal probability using a randomized block design after signing the consent form. Appropriate statistical analyses that took blocking into account were used.
Blinding
The TA and SA participants were blinded as to the randomization status; however, the WC group necessarily knew their randomization status. The treating acupuncturists were unblinded, to know whether to deliver TA or SA. Both TA and SA groups were required to wear eye covers throughout the treatment. We have previously validated our SA technique and delivery protocol. 23 
Intervention
Participants in the TA and SA groups alternated between two groups of points. The TA group included 11 Bfront[ points (governing meridian 20, pericardium meridian 6, heart meridian 7, liver meridian 3, large intestine meridian 4, large intestine meridian 11, kidney meridian 3, spleen meridian 6, stomach meridian 36, ren meridian 17, and ren meridian 6), which were placed with the woman lying supine, and 7 Bback[ points (governing meridian 14, urinary bladder meridian 15, urinary bladder meridian 18, urinary bladder meridian 20, urinary bladder meridian 23, gallbladder meridian 34, and kidney meridian 3), which were accessed in the prone position. The TA needles were inserted 0.5 to 1.5 in and then manually stimulated to reach Bde-qi[ and then retained for 30 minutes. The SA points were selected by our team to be proximate to the TA site (to enhance the blind), but not considered active ( Fig. 1 ). In the SA group, the disposable acupuncture needle and plastic needle tube were placed on the sham points, manipulated without skin penetration and secured with adhesive tape. The TA group had similar use of adhesive tape holding the plastic tubing in place. The WC group received no treatment for 3 months, underwent exit testing, and subsequently had the option of 1 month (12 sessions) of complimentary TA.
Outcome measures
The 7-day hot flash diary was filled out at week 0 (entry) before starting the treatment and at weeks 5 and 12 (exit). Participants recorded the number of mild, moderate, severe, and very severe VMS for 7 consecutive days. The VMS frequency was an average number of hot flashes recorded per day for 7 days. The severity score was computed as the average severity-weighted number of VMS per day. The Menopause-Specific Quality of Life Questionnaire (MENQOL) was also collected as a condition-specific instrument that measures the impact of menopause symptoms on QOL. 24 The MENQOL provided a summary score along with four domain scoresV vasomotor, psychological, physical, and sexualVand was collected at the study entry and exit.
Additional psychosocial measures included the following: (1) the Pittsburgh Sleep Quality Index, 25 which is a self-rated questionnaire that assesses sleep quality and disturbances dur- patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression.
(3) The State-Trait Anxiety Inventory 27 is the definitive instrument for measuring anxiety in adults. It differentiates between the temporary condition of state anxiety and the more general and longstanding quality of trait anxiety.
To evaluate the HPA axis and specifically F production and metabolism, 24-hour urine samples were collected, and an adrenocorticotropic hormone (ACTH) stimulation test was performed. Twenty-four-hour urine samples were assayed for urinary free F and free cortisone, measured by a dichloromethane extraction radioimmunoassay with interassay coefficients of variation of less than 16% over the range of 153 to 798 nmol/L. In addition, urinary steroid metabolite profiles were obtained using gas chromatography/mass spectrometry, as previously reported. 28 These included the F metabolites tetrahydrocortisol (THF), 5>-THF, tetrahydrocortisone, cortols, and cortolones, as well as the adrenal androgen metabolites etiocholanolone and androsterone. The sum of the concentrations of the principal F metabolites (tetrahydrocortisone, THF, 5>-THF, cortolones, and cortols), along with the concentrations of free F and free estrodial, was used as an assessment of the total daily F production, as previously validated. 29 Finally, the production of adrenal androgens was estimated from the content of etiocholanolone + androsterone.
The participants underwent the ACTH stimulation test on the morning of completing the 24-hour urine collection. Because of the effect of the circadian rhythm on adrenocortical function, all stimulations started between 7:00 and 9:00 AM. After a 30-minute rest period after the placement of an intravenous angiocath and heparin lock, three blood samples were drawn at j30, j15, and 0 minutes, and pooled to form the baseline sample (0 minutes). After that, 0.25 mg (one vial) of ACTH-1-24 (Cortrosyn; Organon Co., New Orange, NJ) was injected intravenously for 60 seconds, and a final blood sample was obtained 60 minutes later. Samples were assayed for F, dehydroepiandrosterone (DHEA), and androstenedione. During the initial blood draw at j30 minutes, two other samples were drawn for the measurement of folliclestimulating hormone, estradiol, and estrone. Samples were frozen at j70-C until assayed.
Statistical analysis
Data are presented in tables as means and SD or SE for all continuous variables. Analyses were performed by applying nonparametric statistics. To compare the demographic and symptom variables at baseline, we used the Kruskal-Wallis test. The Kruskal-Wallis test was also applied for comparing the median in the three groups or the Wilcoxon rank sum test for comparing two related groups. All tests of hypotheses were two-sided, with type I error rate of 0.05. A P G 0.05 was considered statistically significant. All statistical analyses were done using SAS 9.1 (SAS Institute Inc., Cary, NC).
RESULTS

Participants
Of the 60 participants enrolled, 27 dropped out, and 33 completed the study. The TA and SA groups both had eight dropouts, with all but two occurring after consent but before treatment began because the participants felt that they could not commit to the 3-month treatment protocol. Most of the 11 WC participants dropped out because of being randomized to a no-treatment group despite being offered free acupuncture after the 3-month waiting period. Compliance to the 36 scheduled treatments in the TA and SA groups was 29 (80%) and 30 (83%), respectively. Demographic and clinical variables at entry are shown in Table 1 . No significant entry differences existed between groups.
Seven-day hot flash diary and MENQOL results
There was no significant difference in the reduction of VMS frequency and severity between the TA and SA groups (exit-entry); however, both groups improved compared with the WC group (Fig. 2) . Most of the reduction of VMS frequency (Q86%) and severity (Q78%) occurred by week 5 of the treatment; however, the SA intensity scores remained static after the initial reduction, whereas the TA scores continued to reduce throughout the 3-month period. The MENQOL results demonstrated a significant improvement in the vasomotor domain and a trend toward improvement in the overall MENQOL in the TA and SA groups compared with the WC group (Table 2) .
Psychosocial results
There were no group differences between entry and exit in the Pittsburgh Sleep Quality Index, Beck Depression Inventory, and the State-Trait Anxiety Inventory. As seen in Table 3 , there are trends for VMS improvement among the subgroups, for which anxiety, depression, and sleep improved in both the TA and SA groups. This relationship became sig-nificant when the TA and SA groups were combined compared with WC.
HPA results
There was no correlation between the 24-hour urinary F and metabolites and frequency or severity of VMS at entry in cross-sectional analysis of all women. Exit 24-hour urinary F measures demonstrated results in the hypothesized direction, where the TA group had the lowest levels of DHEA, F metabolites, and adrenal androgens (etiocholanolone + androsterone; Table 4 ). In addition, we observed a correlation between improved urinary F levels (exit-entry) and improved VMS frequency (exit-entry) in the TA group (r = 0.62, P = 0.043) compared with no correlations in the SA (r = 0.18, P = 0.586) and WC (r = 0.8, P = 0.20) groups. The ACTH stimulation testing results were also in a hypothesized direction; however, these differences seemed to be confounded by baseline differences ( Table 5 ).
In our pilot study, the mean MENQOL vasomotor domain score was 5.68, with an SD of 1.3, among all study participants. With a sample size of 72 women in each group, we would have adequate power (more than 95%) to detect a minimum of 15% difference between SA (or TA) and WC groups at the significant level of 0.025. For the 24-hour urinary measures, our observed baseline mean (SD) of 24-hour F level of 45.2 (16.42) Kg/dL, to detect a clinically relevant 40% reduction in F in women treated with TA (exit level, 27.1) and 15% in the SA group (exit level, 38.4), a sample size of 72 women per group would provide a 96% power with an > value of 0.025, for detecting the estimated differences between TA and SA groups.
DISCUSSION
Our pilot study results demonstrate the feasibility of an appropriately controlled and adequate duration acupuncture intervention trial to more definitively test the impact of TA on VMS. Both the TA and SA interventions improved subjective self-report VMS and MENQOL compared with WC, yet the urinary F and metabolite data reflective of the HPA axis suggest that TA alone may impact this putative mechanistic pathway. These pilot results further suggest correlations between improved depression, anxiety, and sleep scores with improved VMS, supporting further study on the psychological and physiological role of stress in VMS mechanistic pathways and treatment. Determination of clinically relevant differences between TA and SA and WC is important; if TA is not superior to SA, this suggests that TA operates predominantly via a placebo effect and that a simplified approach to acupuncture therapy could be undertaken, reducing the expenses and need for qualified acupuncturists. If SA is not superior to WC, this would suggest that SA does not provide an effect via psychosocial stress reduction and that alternative mechanistic pathways should be explored.
Our results additionally support further testing of the impact of TA on the HPA axis as a mechanistic and therapeutic pathway. From a physiological perspective, TA seems to affect F, F metabolites, and DHEA levels when compared with SA, as well as to correlate to a reduction in VMS. These results are novel and intriguing; if the HPA axis is identified as a mechanistic pathway and treatment target for VMS, a variety of new treatment options should be further explored, including selective serotonin inhibitors, specifically escitalopram, which has been demonstrated to reduce F levels in older adults with generalized anxiety disorder. 30 Additional pharmacological manipulations of F pathways include octreotide, which is a long-acting analog of somatostatin that rapidly reduces ectopic ACTH secretion, as well as the adrenal enzyme inhibitors, metyrapone, or ketoconazole, which reduce F secretion. The current study results also suggest that 24-hour urinary F and F metabolites should be measured as an outcome to reflect the HPA axis as a mechanistic pathway in the definitive clinical trial.
Our current pilot study results add to the existing literature. One prior study that used similar group comparisons (TA, SA, WC) also found significant improvement compared with WC, but no difference between the TA and SA groups for hot flash frequency and index scores, 16 supportive of the concept that TA and SA both probably improve self-report VMS via a placebo effect through psychosocial stress reduction. Their findings of a lack of difference in psychosocial stress and sleep measures between the TA and SA groups further support this concept and mirror our pilot study findings. The current results are also consistent with most studies that exclusively compared TA and SA reporting improved VMS but no group differences, 15, 22, 31, 32 which suggests that further work with objective VMS measures should be pursued. 33 Two of the three studies using individualized treatments rather than predetermined control protocols did report that TA significantly reduced hot flash severity but not frequency compared with SA. 15, 16, 23 These findings may suggest that using adaptable point protocols, as is done in TA clinic settings, may produce a greater reduction in VMS severity. Of the studies examining variables other than VMS, no direct group differences were seen in QOL, sleep dysfunction, or psychological well-being 14,29 similar to our findings for these variables.
Prior work in acupuncture VMS mechanistic pathways has not been particularly fruitful. One study demonstrated that acupuncture decreases the levels of calcitonin geneYrelated peptide, a powerful vasodilator released into circulation during VMS, whereas another study did not. 17, 32 When examining the change in reproductive hormone levels, acupuncture does not seem to exert an effect. 34 In our pilot study, we did not observe a correlation between either urinary F or ACTH stimulation results and VMS, probably due to small sample size and restricted range of values in our study population selected for a high frequency of VMS. Higher F levels have been previously linked to menopause, including VMS, 14 depressed mood, 35 decrease in bone density, 36 arousal, and sleeplessness, 37 as well as greater body fat, especially centripetal obesity 36,38<40 and age. 41, 42 Both acute and chronic F elevations have been demonstrated to be associated with cognitive deficits in humans. 43, 44 In the one study that directly examined the association of VMS and serum F levels, no direct correlation was found. 14 The studies investigating the effects of acupuncture on serum F levels demonstrated mixed results, 45<49 potentially due to methodological limitations. Methods that accurately represent F production and metabolism over longer periods of time, such as 24-hour urinary data, are probably superior in this regard. 50, 51 Our pilot results suggest that 24-hour urinary F collection was, but the ACTH testing was not, sufficiently sensitive and accurate for this purpose.
We increased the duration of treatment in this pilot study compared with prior studies 15, 22, 31 in response to a hypothesis that a longer treatment period could result in distinct clinical outcomes between active and SA groups. Although we observed similar VMS and MENQOL outcomes in this pilot study, we also noted that there seemed to be a stabilization of SA effect after 1 month, compared with the TA group, which continued to decrease throughout the treatment. We hypothesize that we will see a significant TA versus SA group difference with a larger sample size in our longer duration trial design. We also realize, however, that a longer duration of treatment seems to be associated with a higher dropout rate. Given that most VMS improvements occur within 1 month (12 treatments), one solution may be to reduce treatment demand (one to two treatments per week) during months 1 and 3, thus maintaining a longer duration with less burden to the participants.
Limitations
The sample size of this pilot study was, by design, small, and therefore, limited conclusions regarding the intervention effect sizes can be drawn. Our eligibility criteria included at least seven hot flashes per day and at least one missed menstrual cycle or spontaneous or medically induced menopause, which could allow for a heterogeneous group. Future researchers may want to further delineate between perimenopause, postmenopause, and medically induced menopause to control for possible pathophysiological differences. The lack of a consistent method of determining the ideal acupuncture point prescription remains an inherent limitation of acupuncture research; however, the current results are suggestive that our standardized point and delivery protocol may have had the desired mechanistic pathway effect. A further limitation of our study is the reliance on self-reported VMS rather than an objective measure such as the skin conductance ambulatory Biolog monitor. 23, 52 Placebo response seen in SA along with the use of subjective measures enhances the chance of type II error in any study. A recent summary report of the National Institutes of Health workshop on measuring VMS called for studies with both objective biologically measured and subjective self-reported measures of VMS to provide an adequate understanding of efficacy. 53 Given our pilot study findings suggesting a possible physiological mechanistic pathway effect of TA, incorporation of the objective ambulatory VMS monitor, which is now available and validated for VMS measurement 33 into trial designs, is important for objective outcome assessment. Although a previous acupuncture study suggested that increased number of treatments may result in greater between-group differences (TA vs SA), 22 this can also increase placebo response, 54 probably explaining our and prior study results that failed to find a difference between TA and SA. 55 Because F levels follow diurnal patterns and differ day to day, their use as an outcome variable can be controversial. However, because the principal metabolites of F account for more than 95% of F excretion, using their measurements offers a more sensitive means of detecting changes in the rates of F secretion in 24-hour urine samples and lessens the possibility of confusion resulting from circadian rhythm or metabolism. 56 
Implications
The current pilot study results support the conductance of a definitive clinical trial using objective measures and investigating mechanistic pathways to determine the efficacy of TA for VMS in perimenopausal and postmenopausal women. The current study results provide feasibility for trial design and recruitment, identification of primary outcome selection, and variance estimate for the VMS and F outcome measures useful for designing a rigorous clinical trial to guide the application of acupuncture in clinical practice. The use of objective VMS measures and exploration of the role and modulation of the HPA axis are novel additions that should provide clarity and insight into this time-honored non-HT.
CONCLUSIONS
In this pilot, randomized, single-blinded, placebo-controlled study conducted for trial feasibility, outcome determination, and sample size estimation purposes, both the TA and SA interventions improved VMS and menopause-related QOL compared with WC intervention. Improvement in VMS seemed related to improvement in depression, anxiety, and sleep in both TA and SA, whereas TA only seemed to affect the HPA axis as a mechanistic and therapeutic pathway. Given the small sample size, these reported findings should be viewed as preliminary, hypothesis generating, and useful for the planning of a well-designed study including objective measures to determine the efficacy of acupuncture for VMS in perimenopausal and postmenopausal women.
